Corcept Therapeutics shares added 38.7% on August 1, 2025, outpacing the S&P 500's 8.2% gain.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corcept Therapeutics shares added 38.7% on August 1, 2025, outpacing the S&P 500's 8.2% gain.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
Related events
- Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
- Corcept Therapeutics and Twist Bioscience are noted as holdings within the First Trust biotech fund.
- Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
- Corcept Therapeutics disclosed insider trading activity via SEC filings.
Coverage
Newest first; wire copies grouped- ZacksCorcept Therapeutics (CORT) Tops Q2 Earnings Estimates Corcept Therapeutics (CORT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.23 per share. This c